Key Takeaways
- Q1 was a cleanup quarter, not a demand quarter: 41% of sales came from liquidating high-cost inventory, depressing EBITDA margins to ~9%. Herbicides drove the quarter because insecticide demand had not yet started.
- The price-war damage is largely behind them: Chinese dumping and generic price erosion hit hardest in Q4 last year and Q1 this year; management says the bulk of high-cost inventory is now cleared and no major hit is expected after this.
- Q2 is positioned as the breakout quarter: Management called Q2 the highest quarter, with major contribution from new Focused Maharatna products, and explicitly flagged "surprises" on both top line and bottom line.
- The strategy is a deliberate exit from generics: The company is pivoting to patented molecules via Japanese partners, value-added mixtures, and biologicals, while cutting tail on commoditized products. Over 39 patents applied for, 21 built.
- What to watch next quarter: Whether the promised Q2 margin jump to double digits materializes, the pace of inventory reduction toward the ₹550 crore target, and early uptake of the four new product launches.
The Inventory Overhang & Margin Reset
- The Q1 margin story was a liquidation event: 41% of overall sales in Q1 came from clearing high-cost inventory carried from the previous year, which directly compressed EBITDA margins to roughly 9%. The company described Q1 as a period when only herbicide demand was active, with insecticide sales only now beginning.
- The price-war cycle is largely complete: Chinese manufacturers dumped cheaper goods into global markets over the last 6-7 months, triggering a price war in the generic segment. Management stated the large impact came in Q4 last year and Q1 this year, and that "most part is over now," with only some premium stock to work through routinely.
- Inventory reduction is a stated priority: The company is working aggressively to bring inventories down and expressed confidence that by the end of Q2, inventory would be in the range of "₹550 crores minus, not ₹550 crores-plus." All inventory kept for backward integration is expected to be utilized by Diwali, after which plants will be switched to other products.
- Margin recovery path: Management is targeting double-digit EBITDA margin in Q2, with a full-year expectation of 9-10% EBITDA. Beyond this recovery year, the target is 100-150 bps year-on-year improvement at the EBITDA level, with an ambition to "fall in line very shortly with best performers in the industry."
Rajesh Aggarwal: "I'm very, very confident by the end of this quarter, our inventory should be somewhere in the range of INR550 crores minus, not INR550 crores-plus."
The Q2 Bet: New Products & Seasonal Peak
- Q2 is structurally the highest quarter: Insecticide sales start in Q2 as North and Central India seasons kick in (North #1, Central #2, South #3, East trailing). Management stated Q2 will have "the best performance, both in terms of top line and bottom line" and that "there can be surprises in Q2."
- Focused Maharatna products are the engine: Six products launched in the last 3-4 years, promoted during COVID when there was minimum time to push them, are now being scaled as the company's growth engines. Most of these products are not generics and are not under price stress. The company is targeting roughly ₹100 crore per product and expects at least two of the four new Q2 launches to enter the Focused Maharatna range by next year.
- Four new launches in Q2: Three herbicides (Green Expert for paddy, Nakshatra for sugarcane, Opaque for onion) and one insecticide (Supremo SP for paddy and vegetables). All three herbicides are 9(3) mixture products. Launches are scheduled for August and September.
- The product portfolio is being reclassified for focus: About one dozen products sit in Focused Maharatna, over two dozen in Maharatna. New launches will be value-added only; everything else goes under tail cutting. Lower revenue-yielding products are being exited, higher revenue-yielding products added.
Rajesh Aggarwal: "Q2 anyway is the highest. And lot of contribution is going to come from the new products. So yes, Q2, you can take it as it will be having the best performance, both in terms of top line and bottom line, yes. There can be surprises in Q2."
Strategic Pivot: From Generics to IP-Led Portfolio
- The core thesis is an exit from commoditized chemistry: Management's stated strategy is to bring new-technology products to market, slowly cut tail on generics, and give value-added solutions because "ultimately, it is the solution which a customer wants. They don't need the product." Wherever competition is tough and a product is declining, the company will exit, potentially keeping the brand for some time but exiting if the brand also comes under pressure.
- Japanese partnerships are the patent bridge: The company is going into new-generation patented molecules through Japanese partners (including Nissan), making mixtures with Japanese products. It has applied for more than 40 patents and built roughly 21 so far. Two R&D models are in play: backward integration through reverse engineering, and better formulations or new mixtures with IP.
- Biologicals are the next leg: IIL Biologicals Limited will be launched this year, with new product launches after Diwali, catching a small rabi season. The company is filing patents for new biological products and will decide shortly whether the new biological plant goes to Chopanki or Sotanala. Management's long-term vision is that "there will be a time when biological will run parallelly to the chemicals."
- Technology investment is underway: SAP has been upgraded to HANA, BI dashboards are in place, and a CRM package with Salesforce is being implemented to connect with distributors, retailers, farmers, and crop advisers.
Rajesh Aggarwal: "We have a very clear strategy that we will bring the new technology and new technology products to the market. Slowly, we'll be doing the tail cutting of the generics, and we'll give value-added products to the customers because we believe that ultimately, it is the solution which a customer wants. They don't need the product."
Capex & Capacity Build-Out
- Three projects are in motion, all funded internally: The company remains debt-free and is funding all investments through internal resources, though management acknowledged that investment-related expenses are relatively higher and creating some pressure.
- Dahej plant: 95% of expenses are already done. Heavy rainfall delayed the project; production is now planned to start after Diwali, during the Diwali shutdown. Some equipment is still being placed and will be capitalized by Diwali. Changes are planned given the current situation: the company sees no point competing in generic molecules and wants the plant oriented toward mixtures or patented molecules.
- Sotanala (Behror) acquisition: Roughly 15 acres of land acquired with one small plant building already constructed. That plant will be renewed to expedite entry into manufacturing. A two-year project starting post-Diwali 2023: formulation plant, technical synthesis plant, and possibly a biological plant. The location is strategic, sitting between Chopanki and Gujarat on a national highway.
- Capex envelope: ₹150 crore to be spent over the next two years: ₹100 crore at Sotanala, ₹25 crore in SEZ expansion, and ₹25 crore at Dahej. Management did not provide a specific revenue potential for this capex, only reiterating the 20% CAGR target.
Exports & Registrations
- Exports are a near-term drag: The export market is slow due to weak global demand, currency crises in key markets, and payment delays. The company could only match last year's export performance in Q1. The full-year export target is about ₹200 crore, but management expects to end between ₹150 crore and ₹200 crore, implying a possible 20-25% downside.
- High channel inventory in export markets: Inventories in international channels are high because they were built at high prices. The company has been buying stocks at cheaper prices continuously for the last 4-5 months and took MTM losses in March because of those cheaper purchases. Management expects to gain advantages by averaging out and offering competitive prices.
- The registration pipeline is the long-term export story: Over 300 registrations are in process across Latin America, the US, Africa, and Europe. After what management described as "a lot of struggle," registrations are now "coming at speed." The company believes exports are "on the brink of getting a good success" and will "take off in a reasonably big way," though no specific timeline was given.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q2 EBITDA margin | Double-digit margin targeted | Q2 FY24 |
| Full-year EBITDA margin | 9% to 10% | FY24 |
| Inventory reduction | Inventory at ₹550 crore minus | By end of Q2 FY24 |
| Domestic revenue growth | Minimum double-digit growth, top line and bottom line | FY24 |
| Export revenue | ₹150 crore to ₹200 crore (vs ~₹200 crore target) | FY24 |
| New product launches | At least 7-8 products in herbicide, insecticide, fungicide | FY24-FY25 |
| Dahej plant production start | Post-Diwali | FY24 |
| Sotanala project completion | 2-year project | Starting post-Diwali 2023 |
| IIL Biologicals launch | After Diwali, catching small rabi season | FY24 |
| Capex spend | ₹150 crore (₹100 cr Sotanala, ₹25 cr SEZ, ₹25 cr Dahej) | Next 2 years |
| Revenue CAGR | 20% | Next 5 years |
| Annual margin improvement | 100-150 bps year-on-year at EBITDA level | Ongoing, post recovery year |
| FY24 revenue growth | 12% | FY24 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue from operations | ₹639.95 cr, growth of ~14.14% YoY |
| EBITDA margin | 7.13%, impacted by liquidation of high-cost inventory from previous year |
| High-cost inventory liquidation | ~41% of overall sales during the quarter |
| Maharatna products sales | ₹257.74 cr, 61.49% of total branded formulation sales, up from ₹209.06 cr (56.37%) in Q1 FY23 |
| Category-wise sales: Herbicide | 64% of total sales |
| Category-wise sales: Insecticide | 30% of total sales |
| Category-wise sales: Fungicides | 4% of total sales |
| Category-wise sales: Biological and PGRs | ~2% of total sales |
| Region-wise revenue: North | ~36% of total revenue |
| Region-wise revenue: West | ~35% of total revenue |
| Region-wise revenue: South | ~22% of total revenue |
| Region-wise revenue: East | ~7% of total revenue |
| Segment-wise revenue: B2C | ~66% of total revenue |
| Segment-wise revenue: B2B | ~31% of total revenue |
| Total inventory | ~₹600 cr as of the call date, down by ₹250 cr from peak |
| FY24 revenue growth guidance | 12% for the full year |
| FY24 EBITDA margin expectation | 9% to 10% for the full year |
| 5-year revenue CAGR target | 20% |
| Export revenue target for FY24 | ₹150 cr to ₹200 cr, with a possible downfall of 20%–25% in exports assessment |
| Focused Maharatna products contribution | ~35% of turnover, from about 1 dozen products |
| Maharatna products contribution | ~30% of turnover, from about 2 dozen products |
| Gold (generic) products contribution | 30% to 35% of turnover |
| Silver (tail cutting) products contribution | 2% to 3% of turnover |
| Average price cut in generic segment | ~10% plus |
| New product launches lined up in Q2 FY24 | 4 launches, 3 herbicides and 1 insecticide |
| Total capex planned over next 2 years | ₹150 cr, including ₹100 cr for Sotanala, ₹25 cr for SEZ expansion, ₹25 cr for Dahej |
| Dahej plant completion | 95% of expenses already done, production to start post Diwali |
| Chopanki technical plant capacity increase | ~50% |
| Biological revenue contribution | 1.5% to 2% of total turnover |
| Target annual EBITDA margin improvement | 100 to 150 bps year-on-year |
| Inventory reduction target by end of Q2 FY24 | Below ₹550 cr |